Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa

Bibliography

• FRIEDBERG CK: Diseases of the Heart. WB Saunders, Philadelphia, USA (1966):781–785.
   Google Scholar
• DEWOOD MA, SPORES J, HENSLEY GR et al.: Coronary arteriographic findings in acute transmural myocardial infarction. Circulation (1983) 68:39–49.
   PubMed Web of Science ®Google Scholar
• HILLIS WS: The continuing debate: conservative or interventional therapy for unstable coronary disease. Am. J. Cardiol (1997) 80(5A):51E–54E.
   Google Scholar
• DAVIES MJ, THOMAS A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl. I Med. (1984) 310:1147–1150.
   Google Scholar
• ••This is an excellent review of thefundamental role of thrombosis in acute coronary syndromes.
   Google Scholar
• FALK E: Unstable angina with fatal outcome. Dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation (1985) 71:699–708.
   Google Scholar
• ISIS-2 COLLABORATIVE GROUP: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet (1988) 2:349–360.
   PubMed Web of Science ®Google Scholar
• ••This is a landmark study that hasprofoundly influenced the way we practice cardiology today. It is very well written.
   Google Scholar
• COLLINS R, PETO R, BAIGENT C et al.: Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl. J. Med. (1997) 336:847–860.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• HAAS WK, EASTON JD, ADAMS HP Jret al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of strokes in high risk patients. N Engl. J. Med. (1989) 321:501–507.
   Google Scholar
• CAEN JP, CASTALDI PA, LECLERC JC et al.: Congenital bleeding disorders with long bleeding time and normal platelet count. 1. Glanzmann's thrombasthenia. Am. I Med. (1966) 41:4–26.
   Google Scholar
• COLLER BS, SELIGSOHN U, PERETZ H et al.: Glanzmann's thrombasthenia: new insights from an historical perspective. Semin. Hematol (1994) 31:301–311.
   PubMed Web of Science ®Google Scholar
• NURDEN AT, CAEN JP: An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br. Haematol (1974) 28:253–260.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, AGIN PP: Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. I Clinic. Invest. (1977) 60:535–545.
   Google Scholar
• •This paper was one of the first to identify potential targets for a new class of potent anti-platelet agents, the GP IIb/IIIa
   Google Scholar
• •• receptor blockers.
   Google Scholar
• KUNICKI TJ, PIDARD D, ROSA JP et al.: The formation of calcium-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood (1981) 58:268–278.
   PubMed Web of Science ®Google Scholar
• JANG U, LINCOFF AM, PLOW EF, TOPOL EJ: Cell adhesion molecules in coronary artery disease.' Am. Coll. Cardiol (1994) 24: 1591-1601.
   Google Scholar
• PHILLIPS DR, CHARO IF, PARISE LV et al.: The platelet membrane glycoprotein IIb/IIIa complex. Blood (1988) 71: 831–843.
   PubMed Web of Science ®Google Scholar
• CHARO IF, KIEFFER N, PHILLIPS DR: Platelet membrane glycoproteins. In: Hemostasis, and thrombosis: basic principles and clinical practice. Colman RW (Ed.), JB Lippincott, Philadelphia, USA (1994)489–507.
   Google Scholar
• GINSBERG J, KEARON C, HIRSH J: Critical decisions in thrombosis and hemostasis. Decker, Malden, MA, USA (1998).
   Google Scholar
• HYNES RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, CHARO IF, SCARBOROUGH RM: GPIIb-IIIa: the responsive integrin. Cell (1991) 65:359–362.
   PubMed Web of Science ®Google Scholar
• GOLD HK, GIMPLE LW, YASUDA T et al.: Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. Clin. Invest. (1990) 86(2):651–659.
   Google Scholar
• GINSBERG M, PIERSCHBACHER MD, RUOSLAHTI E, MARGUERIE G, PLOW E: Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion. J. Biol. Chem. (1985) 260:3931–3936.
   PubMed Web of Science ®Google Scholar
• PIERSCHBACHER M, HAYMAN EG, RUOSLAHTI E: Synthetic peptide within cell attachment activity of fibronectin. Proc. Natl Acad. Sci. USA (1983) 80:1224–1227.
   PubMed Web of Science ®Google Scholar
• PIERSCHBACHER MD, RUOSLAHTI E: Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc. Nati Acad. Sci. USA (1984) 81:5985–5988.
   PubMed Web of Science ®Google Scholar
• PLOW EF, PIERSCHBACHER MD, RUOSLAHTI E, MARGUERIE GA, GINSBERG MH: The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc. Natl. Acad. Sci. USA (1985) 82:8057–8061.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E, PIERSCHBACHER MD: New perspectives in cell adhesion: RGD and integrins. Science (1987) 238:491–497.
   PubMed Web of Science ®Google Scholar
• PIERSCHBACHER MD, RUOSLAHTI E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 309:30–33.
   PubMed Web of Science ®Google Scholar
• PLOW EF, PIERSCHBACHER MD, RUOSLAHTI E, MARGUERIE G, GINSBERG MH: Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to activated platelets. Blood (1987) 70:110–115.
   PubMed Web of Science ®Google Scholar
• DOLITTLE RE WATT KW, COTTRELL BA, STRONG DD, RILEY M: The amino acid sequence of the alpha-chain of human fibrinogen. Nature (1979) 280:464–468.
   PubMedGoogle Scholar
• HAWIGER J, TIMMONS S, KLOCZEWIAK M, STRONG DD, DOOLITTLE RF: Gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. Proc. Natl. Acad. Sci. USA (1982) 79:2068–2071.
   PubMed Web of Science ®Google Scholar
• HARKER LA, MARAGANORE JM, HIRSH J: Novel antithrombotic agents. In: Hemostasis, and Thrombosis : Basic Principles and Clinical Practice. Colman RW (Ed.), JB Lippincott, Philadelphia, USA (1994):1638–1660.
   Google Scholar
• PLOW EF, GINSBERG MH: Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Frog. Hemost. Thromb. (1989) 9:117–156.
   PubMedGoogle Scholar
• D'SOUZA SE, GINSBERG MH, BURKE TA, PLOW EF: The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its alpha subunit. I Biol. Chem. (1990) 265:3440–3446.
   Google Scholar
• D'SOUZA SE, GINSBERG MH, BURKE TA, LAM SC, PLOW EF: Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science (1988) 242:91–93.
   PubMed Web of Science ®Google Scholar
• CHARO IF, NANNIZZI L, PHILLIPS DR, HSU MA, SCARBOROUGH RM: Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. .1 Biol. Chem. (1991) 266:1415–1421.
   PubMed Web of Science ®Google Scholar
• DENNIS MS, HENZEL WJ, PITTI RIVI et al.: Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. (ArgGlyAsp/fibrinogen receptor/ trigramin/echistatin/kistrin). Proc. Natl. Acad. Sci. USA (1989) 87:2471–2475.
   Web of Science ®Google Scholar
• •This paper provides an interesting insight into the process of drug development.
   Google Scholar
• SCARBOROUGH RM, NAUGHTON MA, TENG W: Design of potent and specific integrin antagonists with high specificity for glycoprotein IIb/IIIa.f Biol. Chem. (1993) 268:1066–1073.
   PubMed Web of Science ®Google Scholar
• CHARO IF, SCARBOROUGH RM, DU MEE CP et al.: Therapeutics I: pharmacodynamics of the glycoprotein IIb/ IIIa antagonist Integrilin: Phase I clinical studies in normal healthy volunteers. Circulation (1992) 86(Suppl. I):1–260.
   Google Scholar
• HANSON SR, KOTZE HF, SAVAGE B et al.: Platelet interactions with Dacron grafts: a model of acute thrombosis in baboons. Arteriosclerosis (1985) 5:595–603.
   PubMedGoogle Scholar
• UTHOFF K, ZEHR KJ, GEERLING R et al.: Inhibition of platelet adhesion during cardiopulmonary by-pass reduces postoperative bleeding. Circulation (1994) 90:269–274.
   Web of Science ®Google Scholar
• HARRINGTON RA, KLEIMAN NS, KOTTKE-MARCHANT K et al: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am.j Cardiol (1995) 76:1222–1227.
   PubMed Web of Science ®Google Scholar
• THE IMPACT II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet (1997) 349:1422–1428.
   PubMed Web of Science ®Google Scholar
• ••This study, together with the PURSUITtrial, was fundamental in getting eptifibatide approved for the treatment of patients undergoing PCI and for patients with acute coronary syndromes.
   Google Scholar
• PHILLIPS DR, TENG W, ARFSTEN A et al.: Effect of calcium on GP IIb/IIIa interactions with Integrilin - enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation (1997) 96:1488–1494.
   PubMed Web of Science ®Google Scholar
• The Physicians Desk Reference. Medical Economics Company, Montvale, NJ, USA (1999).
   Google Scholar
• TCHENG JE: Glycoprotein IIb/IIIa inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. J. Cardiol (1996) 78:35–40.
   PubMedGoogle Scholar
• TCHENG JE, THEL MC, JENNINGS L et al.: Platelet glycoprotein IIb/IIIa receptor blockade with high dose Integrilin Tm in coronary intervention. Results of the PRIDE Study. Ear. Heart J. (1997) 18:P3615.
   Google Scholar
• THE ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356:2037–2044.
   PubMed Web of Science ®Google Scholar
• ••This is the pivotal trial of eptifibatide inPCI.
   Google Scholar
• O'SHEA JC, BULLER CE, CANTOR WJ et al. for the ESPRIT INVESTIGATORS: Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. "AMA (2002) 287:618–621.
   Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl. J. Med. (1998) 339: 436–443.
   PubMed Web of Science ®Google Scholar
• ••This study, together with IMPACT II, wasfundamental in getting eptifibatide approved for the treatment of patients undergoing PCI and for patients with acute coronary syndromes.
   Google Scholar
• OHMAN EM, KLEIMAN NS, GACIOCH G et al.: Combined accelerated tissue-plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled dose ranging trial. Circulation. (1997) 95:846–854.
   PubMed Web of Science ®Google Scholar
• RONNER E, VAN KERTEREN HA, ZIJNEN P et al.: Combined therapy with streptokinase and Integrilin." Am. Coll. CardioL (1998) 31(Suppl. A):191A.
   Google Scholar
• BRENER SJ, ZEYMER U, ADGEY JA et al.: Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the Integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. The INTRO AMI Investigators. J. Am. Coll. Cardiol (2002) 39:377–386.
   PubMed Web of Science ®Google Scholar
• THE EPIC INVESTIGATORS: Use of amonoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl. I Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• THE CAPTURE INVESTIGATORS: Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar